Oxacillin Sodium, also known as cryptocillin, is a semi-synthetic isoxazolyl penicillin antibiotic. Its chemical formula is C19H18N3NaO5S, with a molecular weight of 423.42. This drug is primarily used to treat infections caused by Staphylococcus aureus and Staphylococcus epidermidis that are resistant to penicillin G, including infections in the internal organs, skin, and soft tissues. However, it is generally not suitable for central nervous system infections. This clinical study aims to explore the efficacy and safety of Oxacillin Sodium in various clinical settings.
We provide Oxacillin Sodium CAS 1173-88-2, please refer to the following website for detailed specifications and product information.
Background and Introduction
Oxacillin Sodium is a white powder or crystalline powder that is odorless or slightly odorous. It is highly soluble in water but only slightly soluble in acetone or butanone. As a β-lactam antibiotic and penicillin derivative, Oxacillin Sodium is particularly effective against penicillinase-producing Staphylococcus aureus. It works by inhibiting the synthesis of bacterial cell walls, thereby exerting a bactericidal effect.
The indications for Oxacillin Sodium include the treatment of penicillinase-producing Staphylococcus aureus infections, such as sepsis, endocarditis, pneumonia, and skin and soft tissue infections. It can also be used in mixed infections caused by Streptococcus pyogenes or Streptococcus pneumoniae with penicillin-resistant Staphylococcus aureus.
|
|
|
Literature Review
Previous studies have investigated the use of Oxacillin Sodium in various clinical contexts. For example, one study explored the determination of butyl acetate residue in Oxacillin Sodium using headspace gas chromatography. Another study used differential thermal analysis to determine the thermal degradation kinetic parameters of solid Oxacillin Sodium. These studies provide a foundation for understanding the physicochemical properties and stability of Oxacillin Sodium.
Study Design and Methods
This clinical study was conducted to evaluate the efficacy and safety of Oxacillin Sodium in the treatment of Staphylococcus scalded skin syndrome (SSSS). SSSS is a severe skin infection caused by Staphylococcus aureus, characterized by widespread redness, peeling, and blistering of the skin. The study was conducted at Zhumadian Central Hospital from March 2016 to March 2017.
A total of 125 children with SSSS were enrolled in the study and randomly divided into a control group (62 patients) and a treatment group (63 patients). The control group received intravenous (IV) Oxacillin Sodium for injection at a dose of 12.5 mg/kg added to a small amount of sterile water for injection, three times daily. The treatment group received intramuscular (IM) injection of Xiyanping Injection in addition to the Oxacillin Sodium treatment, at a dose of 10 mg/kg added to a small amount of sterile water for injection, twice daily. Both groups were treated for two weeks.
The primary outcome measure was the clinical efficacy of the treatment, evaluated by comparing the improvement of clinical indicators, white blood cell count, and interleukin-6 (IL-6) levels before and after treatment. Secondary outcome measures included the antipyretic time, Nikolsky's sign negative conversion time, drying time of the bare area, and herpes regression time.
|
|
|
Results
After two weeks of treatment, the clinical efficacy in the control group was 82.26%, while in the treatment group, it was 95.24%. The difference between the two groups was statistically significant (P < 0.05).
The antipyretic time, Nikolsky's sign negative conversion time, drying time of the bare area, and herpes regression time in the treatment group were significantly shorter than those in the control group. The differences between the two groups were also statistically significant (P < 0.05).
Before treatment, the white blood cell count and IL-6 levels in both groups were significantly elevated. After treatment, the white blood cell count and IL-6 levels in both groups decreased significantly, with statistically significant differences within the same group (P < 0.05). Furthermore, the white blood cell count and IL-6 levels in the treatment group after treatment were significantly lower than those in the control group, with statistically significant differences between the two groups (P < 0.05).
Discussion
The results of this study demonstrate that the combination of Xiyanping Injection and Oxacillin Sodium is effective and safe in the treatment of SSSS. The clinical efficacy of the treatment group was significantly higher than that of the control group, indicating that the addition of Xiyanping Injection enhanced the therapeutic effect of Oxacillin Sodium.
The shorter antipyretic time, Nikolsky's sign negative conversion time, drying time of the bare area, and herpes regression time in the treatment group suggest that this combination therapy can more rapidly improve clinical symptoms and promote recovery.
The significant decrease in white blood cell count and IL-6 levels after treatment further confirms the anti-inflammatory and antibacterial effects of this combination therapy. The lower levels of these inflammatory markers in the treatment group compared to the control group indicate a more pronounced anti-inflammatory effect.
Safety Considerations
Oxacillin Sodium can cause allergic reactions, including anaphylactic shock. Therefore, allergy testing should be performed before administration. Gastrointestinal reactions such as nausea, vomiting, abdominal distension, diarrhea, and anorexia may also occur, especially when administered orally. Other adverse reactions include venous inflammation, neurological reactions (such as convulsions, spasms, confusion, and headaches) at high doses, and a tendency to bleed in specific individuals. Some patients may also experience elevated liver enzymes, which usually return to normal after discontinuing the drug.
Conclusion
In conclusion, this clinical study demonstrates that the combination of Xiyanping Injection and Oxacillin Sodium is effective and safe in the treatment of Staphylococcus scalded skin syndrome. The combination therapy significantly improves clinical symptoms, reduces inflammatory markers, and promotes rapid recovery. However, due to the potential for allergic reactions and other adverse effects, careful monitoring and appropriate management are required during treatment.
Future studies should further investigate the long-term efficacy and safety of this combination therapy in larger patient populations and in different clinical settings. Additionally, studies on the pharmacokinetic and pharmacodynamic properties of Oxacillin Sodium in combination with other drugs may provide insights into optimizing treatment regimens and improving patient outcomes.
In summary, Oxacillin Sodium is a valuable antibiotic in the treatment of Staphylococcus aureus infections, particularly those resistant to penicillin G. With appropriate monitoring and management, it can be used safely and effectively to improve patient outcomes.